Verified Nov 2026
Batteries & E-Mobility
·
Canton, Massachusetts
·
Since 1985
Organogenesis is a public regenerative medicine company headquartered in Canton, Massachusetts, founded in 1985 and listed under the ticker ORGO. It employs roughly 500 to 1,000 people and reported revenue of about $482 million for 2024. The company develops and manufactures bioengineered living cell therapies and placental-derived products for advanced wound care, surgical, and sports medicine markets, serving hospitals, outpatient clinics, and wound care centers. Its ISO 13485 certification covers its medical device operations.
Organogenesis at a glance
Revenue
563M
Employees
500-1,000
Founded
1985
Headquarters
Canton, Massachusetts
Ownership
Publicly traded (NASDAQ: ORGO)
Certifications
ISO 13485
Import activity
4
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
4
Named foreign suppliers
3
Top origins
Taiwan · Belgium · United Kingdom
Shared foreign counterparties do not establish that these companies buy from Organogenesis.
What this tells a buyer
The company reported a Biologics License Application submission for ReNu, completed in April 2026, following an earlier FDA meeting announced in December 2025.
Its product portfolio includes bioengineered skin substitutes such as Apligraf and Dermagraft, along with placental and amniotic allografts, and it is held to ISO 13485 certification.
The company is publicly traded, and it reported record revenue in its fourth quarter 2025 financial results released in February 2026.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
STABILITY SIGNALS
Established & strong
41 years in operation (founded 1985).
Publicly listed; no distress event on record.
Holds ISO 13485 certification(s) per public sources.
Overview
Organogenesis is a public regenerative medicine company headquartered in Canton, Massachusetts, founded in 1985 and listed under the ticker ORGO. It employs roughly 500 to 1,000 people and reported revenue of about $482 million for 2024. The company develops and manufactures bioengineered living cell therapies and placental-derived products for advanced wound care, surgical, and sports medicine markets, serving hospitals, outpatient clinics, and wound care centers. Its ISO 13485 certification covers its medical device operations.
At a glance
Attribute | Detail |
|---|---|
Founded | 1985 |
Headquarters | Canton, Massachusetts |
Employees | 500-1,000 |
Revenue | 563M |
Ownership | Publicly traded (NASDAQ: ORGO) |
Primary capability | Batteries & E-Mobility |
Certifications | ISO 13485 |
What Organogenesis makes
Its product portfolio includes bioengineered skin substitutes such as Apligraf and Dermagraft, along with placental and amniotic allografts, and it is held to ISO 13485 certification.
Products and capabilities described on the company's own site include Suspension, LED (source: organogenesis.com).
Certifications
Organogenesis is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — organogenesis.com
Trade and customs footprint
The company reported a Biologics License Application submission for ReNu, completed in April 2026, following an earlier FDA meeting announced in December 2025. US customs bill-of-lading records list 4 inbound shipments across 3 foreign suppliers, with top origins including Taiwan · Belgium · United Kingdom.
Latest developments
2026-11-05 — Organogenesis Holdings Inc. Reports Third Quarter 2026 (globenewswire.com)
2026-04-28 — Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® | Organogenesis Holdings Inc. (organogenesis.com)
2026-04-06 — New York real estate firm acquires Organogenesis property for $68M (pbn.com)
2026-02-26 — Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue | Organogenesis Holdings Inc. (organogenesis.com)
2025-12-15 — Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain | Organogenesis Holdings Inc. (organogenesis.com)
2025-05-29 — Organogenesis open doors to public, showcases products | News | valleybreeze.com (valleybreeze.com)
Facilities
Organogenesis is headquartered in Canton, Massachusetts. Public sources also reference these locations:
Canton, Massachusetts — organogenesis.com
Canton, MA — organogenesis.com
Company details
The company is publicly traded, and it reported record revenue in its fourth quarter 2025 financial results released in February 2026. Organogenesis was founded in 1985, has an estimated 500-1,000 employees, and is headquartered in Canton, Massachusetts. On the LightSource stability read it is rated "Established & strong": 41 years in operation (founded 1985). Publicly listed; no distress event on record. Holds ISO 13485 certification(s) per public sources.
Frequently asked questions
What does Organogenesis make?
Organogenesis is a public regenerative medicine company headquartered in Canton, Massachusetts, founded in 1985 and listed under the ticker ORGO. It employs roughly 500 to 1,000 people and reported revenue of about $482 million for 2024. The company develops and manufactures bioengineered living cell therapies and placental-derived products for advanced wound care, surgical, and sports medicine markets, serving hospitals, outpatient clinics, and wound care centers. Its ISO 13485 certification covers its medical device operations.
Where is Organogenesis headquartered?
Organogenesis is headquartered in Canton, Massachusetts (150 Dan Road, Canton, Massachusetts, 02021).
When was Organogenesis founded?
Organogenesis was founded in 1985.
How big is Organogenesis?
Organogenesis has an estimated 500-1,000 employees, with revenue in the 563M range.
Is Organogenesis publicly traded?
Publicly traded (NASDAQ: ORGO). Public financial figures are drawn from its filings.
What certifications does Organogenesis hold?
Organogenesis lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.